{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:58:13Z","timestamp":1789354693275,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-72392-1","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T13:06:11Z","timestamp":1726146371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation"],"prefix":"10.1038","volume":"14","author":[{"given":"Aileen W.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica D.","family":"Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Hiraragi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan A.","family":"Boldajipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnima","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"72392_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"72392_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"72392_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"72392_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"72392_CR5","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"72392_CR6","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: The phase 1 BNT211\u201301 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"72392_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B. & Rodriguez, A. CAR-T therapies in solid tumors: Opportunities and challenges. Curr. Oncol. Rep. 25, 479\u2013489 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"72392_CR8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1172\/JCI121491","volume":"129","author":"TN Yamamoto","year":"2019","unstructured":"Yamamoto, T. N. et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J. Clin. Investig. 129, 1551\u20131565 (2019).","journal-title":"J. Clin. Investig."},{"key":"72392_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nature22367","volume":"545","author":"M Philip","year":"2017","unstructured":"Philip, M. et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545, 452\u2013456 (2017).","journal-title":"Nature"},{"key":"72392_CR10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998-1013.e1020 (2018).","journal-title":"Cell"},{"key":"72392_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 20, 531\u2013550 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"72392_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"72392_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"72392_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"72392_CR15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"72392_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670\u2013684 (2007).","journal-title":"Immunity"},{"key":"72392_CR17","doi-asserted-by":"publisher","first-page":"eaau0135","DOI":"10.1126\/science.aau0135","volume":"363","author":"SK Vodnala","year":"2019","unstructured":"Vodnala, S. K. et al. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science 363, eaau0135 (2019).","journal-title":"Science"},{"key":"72392_CR18","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","volume":"52","author":"J-R Hwang","year":"2020","unstructured":"Hwang, J.-R., Byeon, Y., Kim, D. & Park, S.-G. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp. Mol. Med. 52, 750\u2013761 (2020).","journal-title":"Exp. Mol. Med."},{"key":"72392_CR19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","volume":"12","author":"SM Kaech","year":"2012","unstructured":"Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12, 749\u2013761 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"72392_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/ni908","volume":"4","author":"AV Gett","year":"2003","unstructured":"Gett, A. V., Sallusto, F., Lanzavecchia, A. & Geginat, J. T cell fitness determined by signal strength. Nat. Immunol. 4, 355\u2013360 (2003).","journal-title":"Nat. Immunol."},{"key":"72392_CR21","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3389\/fimmu.2018.02826","volume":"9","author":"Y Chen","year":"2018","unstructured":"Chen, Y., Zander, R., Khatun, A., Schauder, D. M. & Cui, W. Transcriptional and epigenetic regulation of effector and memory CD8 T cell differentiation. Front. Immunol. 9, 2826 (2018).","journal-title":"Front. Immunol."},{"key":"72392_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nri2379","volume":"8","author":"P Bousso","year":"2008","unstructured":"Bousso, P. T-cell activation by dendritic cells in the lymph node: Lessons from the movies. Nat. Rev. Immunol. 8, 675\u2013684 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"72392_CR23","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nri1245","volume":"3","author":"JB Huppa","year":"2003","unstructured":"Huppa, J. B. & Davis, M. M. T-cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol. 3, 973\u2013983 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"72392_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.immuni.2015.06.023","volume":"43","author":"GD Sckisel","year":"2015","unstructured":"Sckisel, G. D. et al. Out-of-sequence signal 3 paralyzes primary CD4(+) T-cell-dependent immunity. Immunity 43, 240\u2013250 (2015).","journal-title":"Immunity"},{"key":"72392_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41596-019-0249-0","volume":"15","author":"DKY Zhang","year":"2020","unstructured":"Zhang, D. K. Y., Cheung, A. S. & Mooney, D. J. Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds. Nat. Protoc. 15, 773\u2013798 (2020).","journal-title":"Nat. Protoc."},{"key":"72392_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41467-023-36126-7","volume":"14","author":"DKY Zhang","year":"2023","unstructured":"Zhang, D. K. Y. et al. Enhancing CAR-T cell functionality in a patient-specific manner. Nat. Commun. 14, 506 (2023).","journal-title":"Nat. Commun."},{"key":"72392_CR27","doi-asserted-by":"publisher","first-page":"e89580","DOI":"10.1172\/jci.insight.89580","volume":"2","author":"Y Kagoya","year":"2017","unstructured":"Kagoya, Y. et al. Transient stimulation expands superior antitumor T cells for adoptive therapy. JCI Insight 2, e89580 (2017).","journal-title":"JCI Insight"},{"key":"72392_CR28","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616\u20131626 (2005).","journal-title":"J. Clin. Invest."},{"key":"72392_CR29","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.052676899","volume":"99","author":"LE Cheng","year":"2002","unstructured":"Cheng, L. E., Ohl\u00e9n, C., Nelson, B. H. & Greenberg, P. D. Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. U. S. A. 99, 3001\u20133006 (2002).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"72392_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nbt.4047","volume":"36","author":"AS Cheung","year":"2018","unstructured":"Cheung, A. S., Zhang, D. K. Y., Koshy, S. T. & Mooney, D. J. Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat. Biotechnol. 36, 160\u2013169 (2018).","journal-title":"Nat. Biotechnol."},{"key":"72392_CR31","doi-asserted-by":"publisher","first-page":"680834","DOI":"10.3389\/fonc.2021.680834","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Tyrosine kinase ROR1 as a target for anti-cancer therapies. Front. Oncol. 11, 680834 (2021).","journal-title":"Front. Oncol."},{"key":"72392_CR32","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan, A. et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin. Cancer Res. 23, 3061\u20133071 (2017).","journal-title":"Clin. Cancer Res."},{"key":"72392_CR33","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","volume":"24","author":"KT Mueller","year":"2018","unstructured":"Mueller, K. T. et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 24, 6175\u20136184 (2018).","journal-title":"Clin. Cancer Res."},{"key":"72392_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"72392_CR35","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","volume":"132","author":"J Rossi","year":"2018","unstructured":"Rossi, J. et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood 132, 804\u2013814 (2018).","journal-title":"Blood"},{"key":"72392_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"72392_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41389-020-00257-z","volume":"9","author":"M Liu","year":"2020","unstructured":"Liu, M. et al. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis 9, 72 (2020).","journal-title":"Oncogenesis"},{"key":"72392_CR38","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.3390\/cancers14153618","volume":"14","author":"BK Lee","year":"2022","unstructured":"Lee, B. K. et al. Developing ROR1 targeting CAR-T cells against solid tumors in preclinical studies. Cancers (Basel) 14, 3618 (2022).","journal-title":"Cancers (Basel)"},{"key":"72392_CR39","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang, X. & Rivi\u00e8re, I. Clinical manufacturing of CAR T cells: Foundation of a promising therapy. Mol. Ther. Oncol. 3, 16015 (2016).","journal-title":"Mol. Ther. Oncol."},{"key":"72392_CR40","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/PPO.0b013e3181eb33a6","volume":"16","author":"CJ Turtle","year":"2010","unstructured":"Turtle, C. J. & Riddell, S. R. Artificial antigen-presenting cells for use in adoptive immunotherapy. Cancer J. 16, 374\u2013381 (2010).","journal-title":"Cancer J."},{"key":"72392_CR41","doi-asserted-by":"publisher","first-page":"1110028","DOI":"10.3389\/fimmu.2023.1110028","volume":"14","author":"H Xu","year":"2023","unstructured":"Xu, H., Li, N., Wang, G. & Cao, Y. Predictive short\/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed\/refractory B-cell lymphomas. Front. Immunol. 14, 1110028 (2023).","journal-title":"Front. Immunol."},{"key":"72392_CR42","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"72392_CR43","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med."},{"key":"72392_CR44","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328\u20131334 (2020).","journal-title":"Science"},{"key":"72392_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18\u201327 (2017).","journal-title":"Nat. Med."},{"key":"72392_CR46","doi-asserted-by":"publisher","first-page":"eadh1306","DOI":"10.1126\/sciimmunol.adh1306","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun, Q. et al. BCL6 promotes a stem-like CD8(+) T cell program in cancer via antagonizing BLIMP1. Sci. Immunol. 8, eadh1306 (2023).","journal-title":"Sci. Immunol."},{"key":"72392_CR47","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: A phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"72392_CR48","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1158\/0008-5472.CAN-18-0030","volume":"78","author":"IY Jung","year":"2018","unstructured":"Jung, I. Y. et al. CRISPR\/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res. 78, 4692\u20134703 (2018).","journal-title":"Cancer Res."},{"key":"72392_CR49","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019).","journal-title":"Nature"},{"key":"72392_CR50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/bloodadvances.2017011254","volume":"2","author":"CT Petersen","year":"2018","unstructured":"Petersen, C. T. et al. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K\u03b4 inhibitors and VIP antagonists. Blood Adv. 2, 210\u2013223 (2018).","journal-title":"Blood Adv."},{"key":"72392_CR51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-017-0227-4","volume":"5","author":"R Urak","year":"2017","unstructured":"Urak, R. et al. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J. Immunother. Cancer 5, 26 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"72392_CR52","doi-asserted-by":"publisher","first-page":"1026474","DOI":"10.3389\/fmmed.2022.1026474","volume":"2","author":"TB Shabaneh","year":"2022","unstructured":"Shabaneh, T. B. et al. Safety switch optimization enhances antibody-mediated elimination of CAR T cells. Front. Mol. Med. 2, 1026474 (2022).","journal-title":"Front. Mol. Med."},{"key":"72392_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"72392_CR54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 12, 323 (2011).","journal-title":"BMC Bioinform."},{"key":"72392_CR55","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"72392_CR56","unstructured":"Korotkevich, G., et al. Fast gene set enrichment analysis. bioRxiv, 060012 (2021)."},{"key":"72392_CR57","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"72392_CR58","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573-3587.e3529 (2021).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72392-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T14:08:27Z","timestamp":1726150107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72392-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["72392"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-72392-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S.C. is an inventor on a patent application related to the Stim-R technology (US patent 11555177B2). All authors were employees of Lyell Immunopharma at the time of study execution, and may additionally hold stock in Lyell Immunopharma, which has licensed intellectual property related to the Stim-R technology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21331"}}